Update from CARTITUDE-1 | What's new since ASH?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon Research Institute, Nashville, US. In this podcast, he discusses the latest updates from the CARTITUDE-1. This was a phase I/IIb study of JNJ-4528, a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR T)-cell therapy in patients with relapsed/refractory multiple myeloma.

Jesus Berdeja begins by explaining the construct is different to other BCMA CAR T-cell constructs and then goes on to describe the study design, including patient characteristics and eligibility. He then describes the safety results from this study including the late onset of cytotoxic syndrome. He also discusses the overall response rate and measurable residual disease negativity.